FGFR3 and central nervous system cancer: Erdafitinib (JNJ-42756493) is a small molecule pan-FGFR inhibitor that shows promise for specifically inhibiting FGFR3-TACC3 fusions in IDH wild-type glioma in vitro as well as in a Phase I clinical trial (NCT01703481) (37).